參考文獻 |
1. Piret, J. & Boivin, G. Pandemics Throughout History. Front Microbiol 11, 631736 (2020).
2. Kogut, M.H., Lee, A. & Santin, E. Microbiome and pathogen interaction with the immune system. Poultry Sci 99, 1906-1913 (2020).
3. Netea, M.G. et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol 20, 375-388 (2020).
4. Paludan, S.R., Pradeu, T., Masters, S.L. & Mogensen, T.H. Constitutive immune mechanisms: mediators of host defence and immune regulation. Nat Rev Immunol 21, 137-150 (2021).
5. Chaplin, D.D. Overview of the immune response. J Allergy Clin Immunol 125, S3-23 (2010).
6. Nicholson, L.B. The immune system. Essays Biochem 60, 275-301 (2016).
7. Dempsey, P.W., Vaidya, S.A. & Cheng, G. The art of war: Innate and adaptive immune responses. Cellular and Molecular Life Sciences 60, 2604-2621 (2003).
8. Kabelitz, D. & Medzhitov, R. Innate immunity - cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol 19, 1-3 (2007).
9. Iwasaki, A. & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16, 343-353 (2015).
10. Jain, A. & Pasare, C. Innate Control of Adaptive Immunity: Beyond the Three-Signal Paradigm. J Immunol 198, 3791-3800 (2017).
11. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
12. Palm, N.W. & Medzhitov, R. Pattern recognition receptors and control of adaptive immunity. Immunological Reviews 227, 221-233 (2009).
13. Li, D.Y. & Wu, M.H. Pattern recognition receptors in health and diseases. Signal Transduct Tar 6 (2021).
14. Chuang, T.H. & Ulevitch, R.J. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Bba-Gene Struct Expr 1518, 157-161 (2001).
15. Imler, J.L. & Hoffmann, J.A. Toll receptors in innate immunity. Trends Cell Biol 11, 304-311 (2001).
16. Akira, S., Takeda, K. & Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2, 675-680 (2001).
17. Kawai, T. & Akira, S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 17, 338-344 (2005).
18. Underhill, D.M. et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401, 811-815 (1999).
19. Takeuchi, O. et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 13, 933-940 (2001).
20. Takeuchi, O. et al. Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169, 10-14 (2002).
21. Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732-738 (2001).
22. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282, 2085-2088 (1998).
23. Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099-1103 (2001).
24. Chuang, T.H. & Ulevitch, R.J. Cloning and characterization of a sub-family of human Toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 11, 372-378 (2000).
25. Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S. & Sousa, C.R.E. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531 (2004).
26. Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526-1529 (2004).
27. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
28. Bauer, S. et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. P Natl Acad Sci USA 98, 9237-9242 (2001).
29. Chuang, T.H., Lee, J., Kline, L., Mathison, J.C. & Ulevitch, R.J. Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol 71, 538-544 (2002).
30. Trivedi, S. & Greidinger, E.L. Endosomal Toll-like receptors in autoimmunity: mechanisms for clinical diversity. Therapy 6, 433-442 (2009).
31. Averett, D.R., Fletcher, S.P., Li, W., Webber, S.E. & Appleman, J.R. The pharmacology of endosomal TLR agonists in viral disease. Biochem Soc Trans 35, 1468-1472 (2007).
32. Lee, S.M. et al. Recognition of Double-Stranded RNA and Regulation of Interferon Pathway by Toll-Like Receptor 10. Front Immunol 9, 516 (2018).
33. Botos, I., Segal, D.M. & Davies, D.R. The structural biology of Toll-like receptors. Structure 19, 447-459 (2011).
34. Jin, M.S. & Lee, J.O. Structures of the toll-like receptor family and its ligand complexes. Immunity 29, 182-191 (2008).
35. O′Neill, L.A. & Bowie, A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7, 353-364 (2007).
36. Kawai, T. & Akira, S. TLR signaling. Semin Immunol 19, 24-32 (2007).
37. Fitzgerald, K.A. et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 198, 1043-1055 (2003).
38. Meylan, E. et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat. Immunol. 5, 503-507 (2004).
39. Lee, M.S. & Min, Y.J. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 76, 447-480 (2007).
40. O′Neill, L.A.J., Bryant, C.E. & Doyle, S.L. Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer. Pharmacol Rev 61, 177-197 (2009).
41. Anwar, M.A., Shah, M., Kim, J. & Choi, S. Recent clinical trends in Toll-like receptor targeting therapeutics. Med Res Rev 39, 1053-1090 (2019).
42. Dowling, J.K. & Mansell, A. Toll-like receptors: the swiss army knife of immunity and vaccine development. Clin Transl Immunol 5 (2016).
43. Krieg, A.M. et al. Cpg Motifs in Bacterial-DNA Trigger Direct B-Cell Activation. Nature 374, 546-549 (1995).
44. Roman, M. et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 3, 849-854 (1997).
45. Razin, A. & Friedman, J. DNA methylation and its possible biological roles. Prog Nucleic Acid Res Mol Biol 25, 33-52 (1981).
46. Wagner, H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 73, 329-368 (1999).
47. Stein, C.A., Subasinghe, C., Shinozuka, K. & Cohen, J.S. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 16, 3209-3221 (1988).
48. Krieg, A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20, 709-760 (2002).
49. Gursel, M., Verthelyi, D., Gursel, I., Ishii, K.J. & Klinman, D.M. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukocyte Biol 71, 813-820 (2002).
50. Pisetsky, D.S. Mechanisms of immune stimulation by bacterial DNA. Springer Semin Immun 22, 21-33 (2000).
51. Yamamoto, S., Yamamoto, T. & Tokunaga, T. The discovery of immunostimulatory DNA sequence. Springer Semin Immun 22, 11-19 (2000).
52. Chuang, T.H., Lai, C.Y., Tseng, P.H., Yuan, C.J. & Hsu, L.C. Development of CpG-Oligodeoxynucleotides for Effective Activation of Rabbit TLR9 Mediated Immune Responses. Plos One 9 (2014).
53. Jurk, M. & Vollmer, J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. Biodrugs 21, 387-401 (2007).
54. Vollmer, J. & Krieg, A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliver Rev 61, 195-204 (2009).
55. Iho, S., Maeyama, J. & Suzuki, F. CpG oligodeoxynucleotides as mucosal adjuvants. Hum Vacc Immunother 11, 755-760 (2015).
56. Kayraklioglu, N., Horuluoglu, B. & Klinman, D.M. CpG Oligonucleotides as Vaccine Adjuvants. Methods Mol Biol 2197, 51-85 (2021).
57. Delany, I., Rappuoli, R. & De Gregorio, E. Vaccines for the 21st century. EMBO Mol Med 6, 708-720 (2014).
58. Plotkin, S.A. Vaccines: past, present and future. Nat Med 11, S5-11 (2005).
59. Manuja, A., Manuja, B.K., Kaushik, J., Singha, H. & Singh, R.K. Immunotherapeutic potential of CpG oligodeoxynucleotides in veterinary species. Immunopharm Immunot 35, 535-544 (2013).
60. Mutwiri, G. TLR9 agonists: Immune mechanisms and therapeutic potential in domestic animals. Vet Immunol Immunop 148, 85-89 (2012).
61. Ioannou, X.P. et al. Safety of CpG oligodeoxynucleotides in veterinary species. Antisense Nucleic A 13, 157-167 (2003).
62. Lai, C.Y., Yu, G.Y., Luo, Y.P., Xiang, R. & Chuang, T.H. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21. Front Immunol 10 (2019).
63. Champion, C.R. Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant. Ann Pharmacother 55, 783-791 (2021).
64. Hyer, R.N. & Janssen, R.S. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years. Vaccine 37, 5854-5861 (2019).
65. Friesinger, J.G., Birkeland, B. & Thorod, A.B. Human-Animal Relationships in Supported Housing: Animal Atmospheres for Mental Health Recovery. Front Psychol 12 (2021).
66. Brooks, H.L. et al. The power of support from companion animals for people living with mental health problems: a systematic review and narrative synthesis of the evidence. Bmc Psychiatry 18 (2018).
67. Cowie, R.H. et al. Workshop on research priorities for management and treatment of angiostrongyliasis(1). Emerg Infect Dis 18, e1 (2012).
68. Pereira, A. et al. Parasitic zoonoses associated with dogs and cats: a survey of Portuguese pet owners′ awareness and deworming practices. Parasit Vectors 9, 245 (2016).
69. Esch, K.J. & Petersen, C.A. Transmission and epidemiology of zoonotic protozoal diseases of companion animals. Clin Microbiol Rev 26, 58-85 (2013).
70. Roth, J.A. & Spickler, A.R. Duration of immunity induced by companion animal vaccines. Anim Health Res Rev 11, 165-190 (2010).
71. Horzinek, M.C. Vaccine use and disease prevalence in dogs and cats. Vet Microbiol 117, 2-8 (2006).
72. Tamura, K., Dudley, J., Nei, M. & Kumar, S. MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24, 1596-1599 (2007).
73. Schwede, T., Kopp, J., Guex, N. & Peitsch, M.C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Research 31, 3381-3385 (2003).
74. Reevy, G.M. & Delgado, M.M. Are emotionally attached companion animal caregivers conscientious and neurotic? Factors that affect the human-companion animal relationship. J Appl Anim Welf Sci 18, 239-258 (2015).
75. Walsh, F. Human-animal bonds I: the relational significance of companion animals. Fam Process 48, 462-480 (2009).
76. Brooks, H., Rushton, K., Lovell, K., McNaughton, R. & Rogers, A. ′He′s my mate you see′: a critical discourse analysis of the therapeutic role of companion animals in the social networks of people with a diagnosis of severe mental illness. Med Humanit 45, 326-334 (2019).
77. Chur-Hansen, A., Stern, C. & Winefield, H. Gaps in the evidence about companion animals and human health: some suggestions for progress. Int J Evid Based Healthc 8, 140-146 (2010).
78. Reperant, L.A. et al. Companion Animals as a Source of Viruses for Human Beings and Food Production Animals. J Comp Pathol 155, S41-53 (2016).
79. Purewal, R. et al. Companion Animals and Child/Adolescent Development: A Systematic Review of the Evidence. Int J Environ Res Public Health 14 (2017).
80. Day, M.J. Pet-Related Infections. Am Fam Physician 94, 794-802 (2016).
81. Dodds, W.J. Early Life Vaccination of Companion Animal Pets. Vaccines (Basel) 9 (2021).
82. Day, M.J. Immune system development in the dog and cat. J Comp Pathol 137 Suppl 1, S10-15 (2007).
83. Krieg, A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5, 471-484 (2006).
84. Kindrachuk, J. et al. Activation and regulation of toll-like receptor 9: CpGs and beyond. Mini Rev Med Chem 8, 590-600 (2008).
85. Chuang, Y.C. et al. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. Front Immunol 11 (2020).
86. Vollmer, J. et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34, 251-262 (2004).
87. Samulowitz, U. et al. A Novel Class of Immune-Stimulatory CpG Oligodeoxynucleotides Unifies High Potency in Type I Interferon Induction with Preferred Structural Properties. Oligonucleotides 20, 93-101 (2010).
88. Liu, J. et al. A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol Immunol 47, 1083-1090 (2010).
89. Lai, C.Y. et al. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7. Vaccine 32, 5593-5599 (2014). |